Skip to content
Clinical Trials – home

Albert Schweitzer Ziekenhuis

Verified siteinfo

The Netherlands Albert Schweitzerplaats 25, 3318 AT Dordrecht, The Netherlands

  • 50 trials recruiting
  • Chronic lymphocytic leukaemia · Plasma cell myeloma · Acute myeloid leukaemia
  • Adults and children

About Specializations

Albert Schweitzer Ziekenhuis in Dordrecht, The Netherlands specialises in clinical trials of conditions such as Chronic lymphocytic leukaemia, Plasma cell myeloma, Acute myeloid leukaemia, Chronic kidney disease, and other specialisations. This site conducts important research.

Main research areas of the site

Hematologic Malignancies

At Albert Schweitzer Ziekenhuis in Dordrecht, a major share of research focuses on blood cancers, especially multiple myeloma, chronic lymphocytic leukemia, acute myeloid leukemia, and related disorders. These studies are largely aimed at improving treatment effectiveness, deepening disease control, and finding better options for relapsed or hard-to-treat disease.

  • Multiple myeloma and relapsed/refractory disease
  • Chronic lymphocytic leukemia and small lymphocytic lymphoma
  • Acute myeloid leukemia and high-risk myelodysplasia
  • Other hematologic cancers such as lymphoma, polycythemia vera, and myelodysplastic syndrome

Research in this area often compares new combinations or maintenance approaches with current standard care to improve long-term outcomes and reduce the chance of disease return.

Cardiovascular and Metabolic Disease Research

The site also conducts substantial studies in cardiovascular diseases and metabolic disorders, including hypertension, atherosclerotic cardiovascular disease, heart failure, obesity, and dyslipidemia. The overall goal is to test better ways to lower risk, protect organs, and improve long-term health.

  • High cardiovascular risk, stroke prevention, and coronary disease
  • Hypertension and resistant blood pressure control
  • Obesity, mixed dyslipidemia, and related metabolic risk
  • Kidney- and heart-protective treatment strategies

These trials frequently evaluate whether newer therapies can reduce major cardiovascular events or slow progression of disease in people with complex risk profiles.

Kidney, Endocrine, and Metabolic Health

Another important research theme at Albert Schweitzer Ziekenhuis is chronic kidney disease and related endocrine or metabolic conditions such as type 2 diabetes, proteinuria, and thyroid disorders. Studies in this field aim to slow kidney decline, improve symptom control, and support better management of long-term disease.

  • Chronic kidney disease and high proteinuria
  • Kidney disease linked to diabetes or hypertension
  • Thyroid-related conditions such as Graves’ disease and hypothyroidism
  • Metabolic outcomes related to obesity and diabetes care

Many of these trials are designed to determine whether new treatment combinations can better preserve kidney function and improve overall clinical outcomes.

Oncology Beyond Hematology

Solid tumor research is also well represented, with studies in breast cancer, prostate cancer, lung cancer, colorectal cancer, and rectal cancer. The focus is on improving survival, preventing recurrence, and refining treatment strategies for advanced or high-risk disease.

  • Breast cancer, including metastatic and high-risk early disease
  • Prostate cancer, including metastatic castration-resistant disease
  • Non-small cell lung cancer and KRAS-mutated disease
  • Colorectal and rectal cancer, including liver metastases

These trials commonly compare new targeted or combination approaches with established therapy to see whether patients can achieve longer disease control and better outcomes.

Gastrointestinal, Immune, and Inflammatory Conditions

The research portfolio includes digestive system diseases, immune system diseases, and inflammatory disorders such as celiac disease, ulcerative colitis, and rheumatoid arthritis. The purpose of this work is to improve diagnosis, symptom relief, and disease control in conditions that can significantly affect daily life.

  • Celiac disease and gluten-related intestinal injury
  • Ulcerative colitis and other inflammatory bowel conditions
  • Rheumatoid arthritis and immune-mediated inflammation
  • Alcohol-related liver disease and related digestive disorders

Studies in this area often assess whether tailored treatment approaches can better match therapy to individual patient needs and improve quality of life.

Specialized Clinical and Diagnostic Research

Beyond disease-specific treatment studies, the site participates in research on diagnostic techniques, treatment optimization, and health care delivery. This includes work on improving how conditions are detected, how treatment response is measured, and how care can be made more effective and efficient.

  • Diagnostic and therapeutic techniques in routine clinical practice
  • Quality of life and patient-centered treatment decisions
  • Health care organization and cost-effectiveness research
  • Supportive care and treatment tailoring in chronic disease

These studies reflect a broad interest in making care more precise, practical, and responsive to patients living with long-term or complex illnesses.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Albert Schweitzerplaats 253318 AT DordrechtThe Netherlands
Recruiting now
50 trials
Conditions studied
83
Partner status
Verified site

More sites in DordrechtThe Netherlands

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

124 clinical trials

Study of lunsekimig versus placebo in adults with inadequately controlled eosinophilic COPD

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Sponsor:Zenas Biopharma (USA) LLC

A Phase III Study of Survodutide in Adults with Compensated NASH Cirrhosis to Assess Liver Outcomes and Safety

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH

A Phase III trial of BI 456906 weekly injections in adults with NASH and stage 2‑3 liver fibrosis

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH

Study of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Amgen Inc.

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Study on the Effects of Baxdrostat and Dapagliflozin in Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:Astrazeneca AB

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Phase 2 study of MK-7262 and enlicitide decanoate in adults with high lipoprotein(a)

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Merck Sharp & Dohme LLC

Rituximab and venetoclax treatment for 6 vs 26 cycles in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Venetoclax
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Dyslipidaemia

Recruiting

Comparison of Obicetrapib and Bempedoic Acid in Patients with Dyslipidemia at High to Very High Cardiovascular Risk

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bempedoic Acid

Graves' disease

Recruiting

Long-Term Study of Imeroprubart in Adults With Graves' Disease

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.